

Perma-Fix Medical Provides Business Update

Warsaw and Atlanta – November 19, 2014 – Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc., a NASDAQ listed company, today provided a general business update. The Company also announced it will host a business update call today at 2:30 PM Central European time today, Wednesday, November 19, 2014, via webcast on the company's website: www.medical-isotope.com.

Dr. Louis F. Centofanti, CEO of Perma-Fix Medical, commented, "We are pleased to report that in mid-August, the U.S. Patent and Trademark Office granted us very broad intellectual property protection for our proprietary resin technology. This notice of allowance is a major milestone for the company toward advancing our Tc-99m production process. Given the commercial, environmental and political benefits of this process, we have also identified a number of potential opportunities for grant funding from the European Union to commercialize our technology across Europe. We remain extremely encouraged by the outlook for the business, as we believe this technology has the potential to reshape the global supply chain of Tc-99m as it meets global market needs for Tech-99 without the use of uranium."

Dr. Centofanti continued, "We have witnessed growing interest in our medical isotope technology from within the industry—both the U.S. and in Europe. We received positive feedback from industry leaders during the 8th International Conference on Isotopes and Expo in Chicago, organized by the World Council on Isotopes and hosted by the American Nuclear Society on August 25th. Now that our process has been validated at leading institutions in Europe and North America, we are in active discussions with potential strategic partners that will enable us to complete final design of a prototype Tech-99m generator. At that stage, we will move forward with both our FDA and CE applications."

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at http://www.medical-isotope.com.

Contacts:

David K. Waldman Crescendo Communications Europe S.A.

Tel: +1-212-671-1021

Email: pfm@crescendo-ir.com